Correcting a mutation in a patient with a debilitating disease used to seem like science fiction, but the advent of CRISPR editing made this dream a reality. In this webinar, experts will review recent advances in and applications of CRISPR for drug screening and correcting mutations in diseased patients.

Topics to be covered

• Unbiased CRISPR screening approaches for novel therapeutic target discovery
• Finding an HIV cure using CRISPR
  • 1645106448-8604d531afa1e0fc
    Mazhar Adli, PhD
    Associate Professor, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine at Northwestern University
    Mazhar Adli is an associate professor at Northwestern Medical School, the Robert H. Lurie Comprehensive Cancer Center, and the Department of Obstetrics and Gynecology. Adli joined the Feinberg School of Medicine in January of 2020. His research group pioneered efforts to map and identify genome-wide Cas9 off-targets and binding specificities and developed computational CRISPR off-target prediction tools. Aldi aims to understand key drivers of aberrant genome regulation in disease settings such as cancer. To achieve this, his team utilizes genomic and epigenomic mapping, editing, and imaging approaches to understand genome regulation in normal and cancer settings.
  • 1646927112-d17b0cede7d519be
    William Dampier, PhD
    Assistant Professor, Department of Microbiology and Immunology, Drexel University College of Medicine
    William Dampier received his PhD from the School of Biomedical Engineering at Drexel University in 2010, where he used machine learning to study public data on HIV genetic variation, its impact on treatment outcomes, and host binding partners. He joined the faculty of the Drexel College of Medicine in 2012 and began applying his techniques with a large HIV patient cohort in collaboration with Brian Wigdahl, professor and chair of the Department of Microbiology & Immunology at Drexel University College of Medicine. Dampier’s current research focuses on curing HIV using CRISPR-Cas9 gene editing and how to address the challenges of HIV genetic variation.